Abstract: Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.

Abstract: Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.

Abstract: Pharmaceutical compositions may include chloroquine. More specifically, a pharmaceutical composition comprising chloroquine or pharmaceutically acceptable salt(s) thereof for use in the treatment or prevention of a viral lung infection, preferably caused by Betacoronavirus, including but not limited to 2019-nCoV (coronavirus), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV), wherein the pharmaceutical composition is administered by inhalation. An improved delivery into the lungs of a subject with minimum systemic exposure may be achieved.

Abstract: A pharmaceutical composition may include hydroxychloroquine or a pharmaceutically acceptable salt thereof, and a solvent. The pharmaceutical composition may include 1 to 400 mg/mL hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein the solvent is selected from propylene glycol, glycerine, propane-1,3-diol and water or combinations thereof and. The pharmaceutical composition may be suitable for thermal aerosolization. A pharmaceutical composition including hydroxychloroquine or a pharmaceutically acceptable salt thereof may be used in the treatment or prevention of a viral lung infection, wherein the pharmaceutical composition is administered by oral inhalation.

Abstract: A respirator mask wearable by a wearer for protecting the wearer against inhalation of noxious agents (e.g., chemical agents, biological agents, radiological agents, and/or other poisonous or otherwise harmful agents that can cause disease, injury or death), such as a CBRN mask, may be configured to enhance protection of the wearer (e.g., by providing ballistic protection in addition to protecting against noxious agent inhalation) while reducing a burden on the wearer, such as by reducing respiratory resistance, improving visibility, and/or facilitating use of the mask (e.g., connection or disconnection of a filter, conduit, or other air-providing device to or from a breathing interface of the mask).

Abstract: A respirator mask wearable by a wearer for protecting the wearer against inhalation of noxious agents (e.g., chemical agents, biological agents, radiological agents, and/or other poisonous or otherwise harmful agents that can cause disease, injury or death), such as a CBRN mask, may be configured to enhance protection of the wearer (e.g., by providing ballistic protection in addition to protecting against noxious agent inhalation) while reducing a burden on the wearer, such as by reducing respiratory resistance, improving visibility, and/or facilitating use of the mask (e.g., connection or disconnection of a filter, conduit, or other air-providing device to or from a breathing interface of the mask).

Abstract: A respirator mask wearable by a wearer for protecting the wearer against inhalation of noxious agents (e.g., chemical agents, biological agents, radiological agents, and/or other poisonous or otherwise harmful agents that can cause disease, injury or death), such as a CBRN mask, may be configured to enhance protection of the wearer (e.g., by providing ballistic protection in addition to protecting against noxious agent inhalation) while reducing a burden on the wearer, such as by reducing respiratory resistance, improving visibility, and/or facilitating use of the mask (e.g., connection or disconnection of a filter, conduit, or other air-providing device to or from a breathing interface of the mask).

Abstract: Disclosed herein, amongst other things, are various conversion structures for use in a molding system (100, 200). A non-limiting embodiment of the conversion structure includes a standard mold receiver (140, 157) and a mold conversion module (151A, 151B, 151C, 251A, 251B, 251C, 251D, 251E, 251F, 152A, 152B, 152C, 170A, 170B, 170C). The standard mold receiver (140, 57) and the mold conversion module (151A, 151B, 151C, 251A, 251B, 251C, 251D, 251E, 251F, 152A, 152B, 152C, 170A, 170B, 170C) are configured to cooperate, wherein the mold conversion module (151A, 151B, 151C, 251A, 251B, 251C, 251D, 251E, 251F, 152A, 152B, 52C, 170A, 170B, 170C) is receivable in the standard mold receiver (140, 157) for converting a molding configuration of a mold (120).

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-ODE as biomarker.

Abstract: The present invention relates generally to the field of enhancing skin appearance. One aspect of the invention aims to provide a composition comprising 4-oxo-2-pentenoic acid for use in the reduction or prevention of regions of the skin with darker pigmentation. The present invention also relates to cosmetic use of a composition comprising 4-oxo-2-pentenoic acid for the reduction or prevention of regions of the skin with darker pigmentation.

Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to treatment or prevention of liver disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders. A further subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders linked to an insufficient activity of phase II enzymes in the liver.

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using PC-O 40:1 as biomarker.

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The invention provides biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose an in vitro method of diagnosing a lifestyle that allows to delay and/or avoid ageing related chronic inflammatory disorders using p-cresol sulphate as biomarker.

Abstract: A respirator mask wearable by a wearer for protecting the wearer against inhalation of noxious agents (e.g., chemical agents, biological agents, radiological agents, and/or other poisonous or otherwise harmful agents that can cause disease, injury or death), such as a CBRN mask, may be configured to enhance protection of the wearer (e.g., by providing ballistic protection in addition to protecting against noxious agent inhalation) while reducing a burden on the wearer, such as by reducing respiratory resistance, improving visibility, and/or facilitating use of the mask (e.g., connection or disconnection of a filter, conduit, or other air-providing device to or from a breathing interface of the mask).

Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.

Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline.

Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 42:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.

Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of cardiovascular disorders, for example, atherosclerosis, high blood pressure, coronary heart disease, myocardial infarction, angina pectoris, stroke, and heart failure. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cardiovascular disorders.

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose an in vitro method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using phenylacetylglutamine (PAG) as biomarker.

Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:6 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.